Balsam poplar or cottonwood tree. Oil used as antibiotic. Think nutzy protection may need more than cottonwood balm.
Kitty Mayor Ford is outa rehab...even though he said no, no, no. Daddy thinks he's fine even though there's not much time but when he comes back you'll know, know, know.
...the new merger will become Assembly Biosciences...this MB will become ASSMB fur short. Doesn't sound like they will be in the pizza market but butt jokes may still apply.
Chippy has a whole lair of nuts he's protecting from ambulance chasers to JAKI'n the box lobby cysts
he'll start his own chat group somewhere else. This stock's message board is played like a day time soap opera.
when you consider Jakafi that has been on the market for several years, has yet to show any CR's in it's expanding indication treatments it's a no brainer IMET's the superior drug. You want a long term remission and perhaps a possible cure in time you use IMET. You want to reduce spleen size you use Jakafi.
BM there are currently 176,000 patients living with MPNs in the US based on the previous prevalence model study estimate. However using the latest Marketscan design estimates from 2010, the projected prevalence for the MPNs in the US on December 31, 2010 was:
MF – 12, 812
PV – 148, 363
ET – 134, 534
totalling 295,709 with MPN's. These numbers would be sizably larger no doubt had there been a drug such as IMET to help extend their lives.
The data provides compelling evidence to suggest that prevalence of MPNs is much higher than has been reported in the past. This translates potentially into a million plus world wide.
Epidemiology of Myeloproliferative Disorders in US – a real world analysis Poster presented at
ASH 2012 Ruben A. Mesa1, Jyotsna Mehta2*, Hongwei Wang2*, Yanxin Wang2*, Usman Iqbal2*,
Frank Neumann3, Yanzhen Zhang3* and Theodore Colton4*
Epidemiology of Myeloproliferative neoplasms (MPN) in the United States. Leuk Lymphoma. Epub 2013 Jyotsna Mehta1, Hongwei Wang2, Usman Iqbal2, Ruben Mesa1
1Mayo Clinic Arizona, Scottsdale, AZ
2Global Evidence & Value Development, Sanofi, MA
3Research and Development, Sanofi, Oncology, Cambridge, MA
4Department of Epidemiology, Boston University, Boston, MA
Sean Williams writes "On one hand, Geron's imetelstat is extremely intriguing in that it's the first investigational therapy to show clinical benefits in treating MF and delivering partial responses in its IST rather than simply mitigating symptoms. However, Geron's pipeline lacks depth, and its full clinical hold pertaining to its in-house studies for polycythemia vera and multiple myeloma remains in place. It's another stock I'm perfectly happy to watch from afar."
He fails to mention IMET has delivered Complete Clinical Responses or remissions as well as Partial Clinical Improvements for several MF patients. If Geron's pipeline lacks depth INCY's is nothing but a smokescreen billowing $billions of profits. Sean will be watching the SP double from afar when the complete clinical hold is lifted.
...and builds as the full hold excitement gains traction. Dropping _dead how can the FDA release the hold on one indication and not the others? Remember this is still in trial.
"Why can't we get started?"
...because of the multi billion dollar Jakafi lobby. MF, PV, ET are but a few indications Jakafi has been given fast tracked FDA approval for. They are in the process of applying for more 'make u feel slightly better' applications. IMET presents a direct threat to them as hands down it is an far more efficacious drug than RUX with considerably fewer side effects. RU has never shown CR or PR in any clinical trials yet the FDA has licensed them to the tune of a billion + market annually. Billions are at stake here. No one accepts "may the best man win" laying down...never holds true when big money's at stake.
I'd be more suspicious of JAKAFI lobby's verbiage and influence. If Zhen or Silver were balanced in their perspective critique they would have given Ruxonitlit a thumbs down long ago. So far Silver`s only praise for existing feel better treatment and Zhen accepting death over fighting for life is not the only route for MF patients to follow.
Not saying IMET will cure all MF patients but a pre screening of new entry trial patients could easily achieve 100% efficacy. The MAYO was using IMET as a last effort to save these patients lives. Some are still living and with some their disease progression may have gone beyond the drug`s ability to reverse their cancer or simply not effective on it.
...well so far SP is up 2 points from May's lo when you started your "bash" campaign opti
The full hold on IMET delayed Geron’s plans for conducting a phase II study in myelofibrosis scheduled to commence in the first half of this year. This will get lifted as the partial clinical hold on the MF investigator-sponsored study was lifted on Wednesday this past week following data submitted by the MAYO supporting no liver toxicity concerns. This delay due to the partial clinical hold can now proceed forward wrt MF trials. How can they stop one study and hold up another for the same indication?
The full clinical hold still covers the hold for polycythemia vera and multiple myeloma. Two areas that are not a priority for the company for the time being and further in question as to required data submission and availability of such data by the company... not sure if the MAYO data will be enough to appease the FDA to release the remainder of this clinical hold for other cancer indications at this time.
think of it
of course it's a game changer...how can the FDA not release the hold on GERN given reversibility data given to them on IMET from the MAYO.
Now GERN is cautious not to step on INCY's golden goose's web feet and froie gras spleen otherwise this short assault may succeed. Jaki's going fur $100 sp with their 'feel good' poly vera approval.